Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
A placebo-controlled trial in which male and female outpatients with an opioid use disorder
who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to
lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered
XR-NTX if after completing withdrawal.